Last updated: April 25, 2026
Forest Laboratories LLC v. Breckenridge Pharmaceutical Inc. | 1:14-cv-01504: Litigation Summary and Patent/Regulatory Posture
What is the case and what was challenged?
Forest Laboratories LLC v. Breckenridge Pharmaceutical Inc., No. 1:14-cv-01504 is a Hatch-Waxman Act dispute brought by Forest against Breckenridge over an ANDA-based drug launch targeting Forest’s branded product(s) in the U.S. District Court for the District of Delaware (caption indicates Delaware venue; docket number format aligns to that district).
The case posture is consistent with Hatch-Waxman “patent listing vs. ANDA” litigation, where the brand owner asserts that the generic applicant’s ANDA contains invalid or non-infringing certifications as to one or more listed patents.
What did the court address and what filings mattered?
The docket and briefing structure in Hatch-Waxman actions typically clusters around these issues:
- Validity challenges raised in response to a Paragraph IV or other certification strategy by the ANDA applicant.
- Infringement contentions tied to claim charts and product-by-product ANDA allegations.
- Procedural entry points that frequently include motion practice on:
- case schedule,
- claim construction,
- summary judgment,
- or injunction standards tied to patent outcomes.
However, the request requires a litigation summary and patent/regulatory analysis. A complete and accurate analysis depends on docket-specific facts: asserted patents (numbers and titles), certification type (Paragraph IV vs. Paragraph III, etc.), the court’s rulings (Markman orders, summary judgment, trial outcomes), and the final disposition (dismissal, settlement terms affecting launch, or judgment).
Those docket-specific elements are not provided in the prompt, and generating them would require inventing details.
What outcome occurred?
The request asks for a litigation summary and analysis, which requires the case outcome (judgment or settlement, which patents were involved, and whether a launch was enjoined). No outcome data is included, so a factual summary cannot be produced without fabricating court holdings.
Case analytics investors use: what can and cannot be concluded from the identifier alone
Is it a Hatch-Waxman “Paragraph IV” case, and which patents were at issue?
A case with this caption and docket number is plausibly Hatch-Waxman, but the asserted patent list and certification basis must be stated from the record. Without the patents and the court’s disposition, no defensible conclusions about:
- strength of Forest’s patent portfolio in this dispute,
- likelihood of infringement findings,
- or expected generic entry timing
can be made.
What is the legal effect on market entry and approvals?
In Hatch-Waxman disputes, market effects hinge on:
- whether the court found invalidity or non-infringement,
- whether an injunction issued,
- whether there was a settlement converting litigation into a delayed launch,
- and whether later Orange Book listings changed the competitive timeline.
Without the outcome and any settlement or injunction language from the docket, a correct analysis is not possible.
Evidence-based litigation breakdown (requires docket record)
To deliver the Bloomberg-style litigation analysis you requested, the analysis must include exact citations to:
- asserted patent numbers and claim groupings,
- ANDAs and product strength/formulation, and
- court orders (claim construction, dispositive motions, final judgment).
None of those record elements are included in the prompt. Per constraints, the response must not be produced with missing or fabricated facts.
Key Takeaways
- The case identifier alone is insufficient to produce an accurate litigation summary and patent/regulatory analysis for Forest v. Breckenridge.
- A compliant, decision-grade summary requires the asserted patents, certification type, and court disposition, none of which are supplied here.
- No factual outcome, injunction status, or launch impact can be stated without docket-specific findings.
FAQs
1) Is this case about a Paragraph IV certification?
A factual answer requires the ANDA certification type shown in the docket; it is not provided here.
2) Which patents did Forest assert?
The patent list is not provided in the prompt.
3) Did the court find invalidity or non-infringement?
The judgment or dispositive ruling is not provided in the prompt.
4) Was there a settlement or injunction?
Settlement or injunction terms require docket-specific orders or settlement documentation, not provided.
5) What was the impact on generic launch timing?
Launch impact requires the case outcome and any post-judgment agreements, which are not included.
References
[1] Forest Laboratories LLC v. Breckenridge Pharmaceutical Inc., No. 1:14-cv-01504 (D. Del.).
